B-intervention	0	11	Gemcitabine
I-intervention	11	12	,
I-intervention	13	23	epirubicin
I-intervention	23	24	,
I-intervention	25	28	and
I-intervention	29	39	paclitaxel
O	40	46	versus
B-control	47	59	fluorouracil
I-control	59	60	,
I-control	61	71	epirubicin
I-control	71	72	,
I-control	73	76	and
I-control	77	93	cyclophosphamide
O	94	96	as
O	97	102	first
O	102	103	-
O	103	107	line
O	108	120	chemotherapy
O	121	123	in
O	124	134	metastatic
O	135	141	breast
O	142	148	cancer
O	148	149	:
O	150	151	a
O	152	159	Central
O	160	168	European
O	169	180	Cooperative
O	181	189	Oncology
O	190	195	Group
O	196	209	International
O	209	210	,
O	211	222	multicenter
O	222	223	,
O	224	235	prospective
O	235	236	,
O	237	247	randomized
O	248	253	phase
O	254	257	III
O	258	263	trial
O	263	264	.

O	265	268	The
O	269	279	objectives
O	280	282	of
O	283	287	this
O	288	293	phase
O	294	297	III
O	298	303	trial
O	304	308	were
O	309	311	to
O	312	319	compare
O	320	323	the
O	324	328	time
O	329	331	to
O	332	343	progressive
O	344	351	disease
O	352	353	(
O	353	357	TtPD
O	357	358	)
O	358	359	,
O	360	367	overall
O	368	376	response
O	377	381	rate
O	382	383	(
O	383	386	ORR
O	386	387	)
O	387	388	,
O	389	396	overall
O	397	405	survival
O	405	406	,
O	407	410	and
O	411	419	toxicity
O	420	422	of
O	423	434	gemcitabine
O	434	435	,
O	436	446	epirubicin
O	446	447	,
O	448	451	and
O	452	462	paclitaxel
O	463	464	(
O	464	467	GET
O	467	468	)
O	469	475	versus
O	476	488	fluorouracil
O	489	490	(
O	490	492	FU
O	492	493	)
O	493	494	,
O	495	505	epirubicin
O	505	506	,
O	507	510	and
O	511	527	cyclophosphamide
O	528	529	(
O	529	532	FEC
O	532	533	)
O	534	536	as
O	537	542	first
O	542	543	-
O	543	547	line
O	548	555	therapy
O	556	558	in
O	559	567	patients
O	568	572	with
O	573	583	metastatic
O	584	590	breast
O	591	597	cancer
O	598	599	(
O	599	602	MBC
O	602	603	)
O	603	604	.

O	605	611	Female
O	612	620	patients
O	621	625	aged
B-age	626	628	18
I-age	629	631	to
I-age	632	634	75
I-age	635	640	years
B-eligibility	641	645	with
I-eligibility	646	651	stage
I-eligibility	652	654	IV
I-eligibility	655	658	and
I-eligibility	659	669	measurable
I-eligibility	670	673	MBC
O	674	678	were
O	679	687	enrolled
O	688	691	and
O	692	700	randomly
O	701	709	assigned
O	710	712	to
O	713	719	either
O	720	731	gemcitabine
O	732	733	(
O	733	734	1
O	734	735	,
O	735	738	000
O	739	741	mg
O	741	742	/
O	742	743	m
O	743	744	(
O	744	745	2
O	745	746	)
O	746	747	,
O	748	752	days
O	753	754	1
O	755	758	and
O	759	760	4
O	760	761	)
O	761	762	,
O	763	773	epirubicin
O	774	775	(
O	775	777	90
O	778	780	mg
O	780	781	/
O	781	782	m
O	782	783	(
O	783	784	2
O	784	785	)
O	785	786	,
O	787	790	day
O	791	792	1
O	792	793	)
O	793	794	,
O	795	798	and
O	799	809	paclitaxel
O	810	811	(
O	811	814	175
O	815	817	mg
O	817	818	/
O	818	819	m
O	819	820	(
O	820	821	2
O	821	822	)
O	822	823	,
O	824	827	day
O	828	829	1
O	829	830	)
O	831	833	or
O	834	836	FU
O	837	838	(
O	838	841	500
O	842	844	mg
O	844	845	/
O	845	846	m
O	846	847	(
O	847	848	2
O	848	849	)
O	849	850	,
O	851	854	day
O	855	856	1
O	856	857	)
O	857	858	,
O	859	869	epirubicin
O	870	871	(
O	871	873	90
O	874	876	mg
O	876	877	/
O	877	878	m
O	878	879	(
O	879	880	2
O	880	881	)
O	881	882	,
O	883	886	day
O	887	888	1
O	888	889	)
O	889	890	,
O	891	894	and
O	895	911	cyclophosphamide
O	912	913	(
O	913	916	500
O	917	919	mg
O	919	920	/
O	920	921	m
O	921	922	(
O	922	923	2
O	923	924	)
O	924	925	,
O	926	929	day
O	930	931	1
O	931	932	)
O	932	933	.

O	934	938	Both
O	939	947	regimens
O	948	952	were
O	953	965	administered
O	966	971	every
O	972	974	21
O	975	979	days
O	980	983	for
O	984	985	a
O	986	993	maximum
O	994	996	of
O	997	1002	eight
O	1003	1009	cycles
O	1009	1010	.

O	1011	1018	Between
O	1019	1026	October
O	1027	1031	1999
O	1032	1035	and
O	1036	1044	November
O	1045	1049	2002
O	1049	1050	,
B-total-participants	1051	1054	259
O	1055	1063	patients
O	1064	1065	(
O	1065	1068	GET
O	1068	1069	,
O	1070	1071	n
O	1072	1073	=
B-intervention-participants	1074	1077	124
O	1077	1078	;
O	1079	1082	FEC
O	1082	1083	,
O	1084	1085	n
O	1086	1087	=
B-control-participants	1088	1091	135
O	1091	1092	)
O	1093	1097	were
O	1098	1106	enrolled
O	1106	1107	.

O	1108	1116	Baseline
O	1117	1132	characteristics
O	1133	1137	were
O	1138	1142	well
O	1143	1151	balanced
O	1152	1158	across
O	1159	1168	treatment
O	1169	1173	arms
O	1173	1174	.

O	1175	1180	After
O	1181	1182	a
O	1183	1189	median
O	1190	1192	of
O	1193	1195	20
O	1195	1196	.
O	1196	1197	4
O	1198	1204	months
O	1205	1207	of
O	1208	1214	follow
O	1214	1215	-
O	1215	1217	up
O	1217	1218	,
B-outcome	1219	1225	median
I-outcome	1226	1230	TtPD
O	1231	1234	was
B-iv-cont-median	1235	1236	9
I-iv-cont-median	1236	1237	.
I-iv-cont-median	1237	1238	1
I-iv-cont-median	1239	1245	months
O	1246	1249	and
B-cv-cont-median	1250	1251	9
I-cv-cont-median	1251	1252	.
I-cv-cont-median	1252	1253	0
I-cv-cont-median	1254	1260	months
O	1261	1263	in
O	1264	1267	the
O	1268	1271	GET
O	1272	1275	and
O	1276	1279	FEC
O	1280	1284	arms
O	1284	1285	,
O	1286	1298	respectively
O	1299	1300	(
O	1300	1301	P
O	1302	1303	=
O	1304	1305	.
O	1305	1308	557
O	1308	1309	)
O	1309	1310	.

O	1311	1314	The
B-outcome	1315	1318	ORR
O	1319	1322	was
B-iv-bin-percent	1323	1325	62
I-iv-bin-percent	1325	1326	.
I-iv-bin-percent	1326	1327	3
I-iv-bin-percent	1327	1328	%
O	1329	1331	in
O	1332	1335	the
O	1336	1339	GET
O	1340	1343	arm
O	1344	1345	(
O	1345	1346	n
O	1347	1348	=
B-intervention-participants	1349	1352	114
O	1352	1353	)
O	1354	1357	and
B-cv-bin-percent	1358	1360	51
I-cv-bin-percent	1360	1361	.
I-cv-bin-percent	1361	1362	2
I-cv-bin-percent	1362	1363	%
O	1364	1366	in
O	1367	1370	the
O	1371	1374	FEC
O	1375	1378	arm
O	1379	1380	(
O	1380	1381	n
O	1382	1383	=
B-control-participants	1384	1387	129
O	1387	1388	;
O	1389	1390	P
O	1391	1392	=
O	1393	1394	.
O	1394	1397	093
O	1397	1398	)
O	1398	1399	.

B-outcome	1400	1405	Grade
I-outcome	1406	1407	3
I-outcome	1408	1411	and
I-outcome	1412	1413	4
I-outcome	1414	1424	toxicities
O	1424	1425	,
O	1426	1435	including
B-outcome	1436	1447	neutropenia
O	1447	1448	,
B-outcome	1449	1465	thrombocytopenia
O	1465	1466	,
B-outcome	1467	1473	anemia
O	1473	1474	,
B-outcome	1475	1485	stomatitis
O	1485	1486	,
B-outcome	1487	1499	neurosensory
I-outcome	1500	1508	toxicity
O	1508	1509	,
O	1510	1513	and
B-outcome	1514	1521	allergy
O	1521	1522	,
O	1523	1531	occurred
O	1532	1545	significantly
O	1546	1550	more
O	1551	1556	often
O	1557	1559	in
O	1560	1563	the
O	1564	1567	GET
O	1568	1571	arm
O	1571	1572	.

O	1573	1575	No
O	1576	1587	significant
O	1588	1599	differences
O	1600	1602	in
O	1603	1608	terms
O	1609	1611	of
B-outcome	1612	1616	TtPD
O	1617	1620	and
B-outcome	1621	1624	ORR
O	1625	1629	were
O	1630	1638	observed
O	1639	1646	between
O	1647	1650	the
O	1651	1654	two
O	1655	1664	treatment
O	1665	1669	arms
O	1669	1670	.

O	1671	1680	Treatment
O	1680	1681	-
O	1681	1688	related
O	1689	1697	toxicity
O	1698	1701	was
O	1702	1708	higher
O	1709	1711	in
O	1712	1715	the
O	1716	1719	GET
O	1720	1723	arm
O	1723	1724	.
